Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Januvia Ranked No. 1 in HP, GP Markets: RepTrack Survey
March 21, 2011
- JMA Urges Korosho to Make Quick Decision Regarding ActHIB, Prevnar
March 21, 2011
- Massive Earthquake, Tsunami Hit Northern Japan Paralyzing Business Activities
March 21, 2011
- ActHIB Recalled due to Contamination
March 21, 2011
- Nihon Medi-Physics Provides Radiocesium Decontaminating Agent Free of Charge
March 21, 2011
- Applications Expected for Inactivated Polio Vaccines at End of 2011
March 21, 2011
- R&I to Downgrade Terumo Following Announcement of Acquisition of CaridianBCT
March 21, 2011
- Korosho to Extend HPV Vaccination Period for Girls Currently in 1st Grade of Senior High School
March 21, 2011
- JACDS May Violate Antimonopoly Act by Calling on Members Not to Offer Point Cards
March 21, 2011
- MSD K.K. Submits NDA for Caspofungin
March 21, 2011
- Nichiyakubo to Call For Improvement of Drug Substance Import System
March 21, 2011
- Eli Lilly's Gemzar Receives Add'l Indication for Ovarian Cancer
March 21, 2011
- Astellas to Challenge New Field of Regenerative Medicine
March 21, 2011
- Herceptin Approved for Gastric Cancer as Add'l Indication
March 21, 2011
- Shionogi Terminates Development of S-2367 for Obesity Drug in the US, Europe
March 21, 2011
- Stiripentol Designated as Orphan Drug
March 21, 2011
- Daiichi Sankyo to Invite Joint Drug Discovery Projects for Open Innovation
March 21, 2011
- Janssen: Stelara for Psoriasis
March 21, 2011
- Eisai Ties Up with Epizyme for Cancer Treatments
March 21, 2011
- Sales of Ethical Drugs Up 3.9% in January: Crecon Research & Consulting
March 21, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…